Lifecare ASA

Director's Dealing • Jul 2, 2024

Lifecare ASA: Mandatory notification of trade

Lifecare ASA: Mandatory notification of trade

Reference is made to the previous stock exchange announcements published by

Lifecare ASA (the "Company") regarding the completion of the Rights Issue.

Hannibal Invest AS, a company closely associated with Hans Hekland, board

member of the Company, has 27 June 2024 subscribed 65,599 shares at a price of

NOK 1,52442 per share, as compensation for the underwriting commitment made in

connection with the Rights Issue. Please see the attached PDMR-form for

further details.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-07-02 17:25 CEST.